bioRxivCancer BiologyPreprint
Interferon Restores Antigen Presentation and Sensitizes Medulloblastoma to T Cell Killing
Tanja EisemanniD, Meher Beigi Masihi, Theophilos TzaridisiD, Veronika I. PisteriD, Isaac Youm, Kendall R. ChambersiD, Aditi DuttaiD, Alexander T. WenzeliD, Koei ChiniD, Scott L. PomeroyiD, Jill P. MesiroviD, Ernest FraenkeliD, Anindya BagchiiD, Lukas CháveziD, Robert J. Wechsler‐ReyaiD
Abstract
Medulloblastomas are commonly considered immunologically cold and refractory to immunotherapy. One contributing factor to their low immunogenicity is impaired antigen presentation, which allows tumor cells to escape from cytotoxic T cells. Here we use a syngeneic mouse model of medulloblastoma to study the role of CD8+ T cells in medulloblastoma growth. We demonstrate that despite low expression of MHC Class I on tumor cells, depletion of CD8+ T cells accelerates tumor growth, whereas adoptive transfer of tumor-reactive CD8+ T cells prolongs survival. These anti-tumor effects rely on T cells secreting interferon gamma (IFN{gamma}), which induces MHC class I on tumor cells and facilitates tumor cell killing by T cells. Notably, this response is essential for CD8+ T cell-mediated tumor attack, as blocking IFN{gamma} signaling in vivo abrogates MHC class I induction and eliminates the beneficial effect of T cells. Importantly, delivering IFN{gamma} directly into tumors via convection-enhanced delivery (CED) enhances CD8+ T cell-mediated killing of tumor cells and significantly prolongs survival in tumor-bearing mice. These studies highlight the importance of T cells in controlling brain tumor growth and the value of IFN{gamma} as an adjuvant for T cell-based immunotherapy.
- organism: mouse
- assay: bulk RNA-seq
- research focus: host-pathogen & immune response
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- EphA2 and Phosphoantigen-Mediated Selective Killing of Medulloblastoma by γδT Cells Preserves Neuronal and Stem Cell Integrity
Lola Boutin, Mingzhi Liu, … Margareta Wilhelm·OncoImmunologyPeer-reviewed·Apr 7, 2025
- Conventional dendritic cells type I with an enhanced type-I-IFN signaling underpin anti-tumor immune responses in brain metastases
Fiona James, Alena Revalová, … Mihaela Lorger·bioRxiv·Jul 8, 2026
- IRF8-driven reprogramming of the immune microenvironment enhances anti-tumor adaptive immunity and reduces immunosuppression in murine glioblastoma
M. Montoya, S. A. Collins, … H. Okada·bioRxiv·Apr 2, 2024
- MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors
M. Kilian, R. Sheinin, … M. Platten·Cancer CellPeer-reviewed·Feb 1, 2023
- IFNgamma-dependent remodelling of the myeloid landscape underlies control of IFNgamma-insensitive tumours
V. W. C. Lau, G. Mead, … A. Gerard·bioRxiv·Mar 25, 2024
- Intratumoral gene delivery of 4-1BBL boosts IL-12-triggered anti-glioblastoma immunity
Taral R. Lunavat, Lisa Nieland, … Koen Breyne·bioRxiv·Feb 3, 2025